Catalog No.
Product Name
Application
Product Information
Citations
-
ATM Kinase Activity Inducer
GJ071 oxalate is an ATM kinase activity inducer that targets ataxia telangiectasia mutated (ATM) kinase. It is specifically designed for use in A-T cells harboring homozygous TGA or TAG stop codons. This compound enhances ATM kinase activity, facilitating studies on DNA damage response mechanisms and therapeutic strategies for ataxia telangiectasia and related disorders. -
ATM Inhibitor
(S)-WSD0628 is a selective ATM inhibitor that effectively inhibits the phosphorylation of ATM in MCF-7 cells, with an IC50 of less than 100 nM. This compound demonstrates radiosensitizing properties, enhancing the efficacy of radiotherapy in cancer treatments. Additionally, (S)-WSD0628 is capable of crossing the blood-brain barrier, making it a valuable tool for research applications in neuro-oncology and other fields where central nervous system exposure is essential. -
ATR Inhibitor
ATR-IN-9 is a selective inhibitor of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR), with an IC50 value of 10 nM, indicating its high potency. This compound is useful for research applications involving cell cycle regulation, DNA damage response, and cancer therapeutics, offering insights into the role of ATR in cellular processes. Its ability to modulate ATR activity makes it a valuable tool in studies focused on tumor biology and therapeutic resistance. -
ATR Inhibitor
ATR-IN-14 is a potent ATR kinase inhibitor that effectively disrupts ATR signaling pathways by inhibiting CHK1 protein phosphorylation, achieving 98.03% inhibition at 25 nM. With demonstrated anticancer activity in LoVo cells, ATR-IN-14 exhibits an IC50 of 64 nM. This reagent is valuable for researchers investigating DNA damage response mechanisms and therapeutic strategies in cancer treatment. -
ATR Inhibitor
ATR-IN-24 is a potent ATR (Ataxia Telangiectasia and Rad3-related protein) inhibitor. It exhibits significant anticancer activity by interfering with the DNA damage response pathway, thereby enhancing the effects of DNA-damaging agents. This compound is valuable for research applications targeting cancer cell proliferation and sensitivity to chemotherapy, making it an important tool for studies on tumor biology and treatment resistance. -
ATM Inhibitor
ATM Inhibitor-3 is a potent and selective inhibitor of the ataxia-telangiectasia mutated (ATM) kinase, demonstrating an IC50 of 0.71 nM. This compound specifically inhibits the PI3K kinase family, making it relevant for research in cancer biology and DNA damage response pathways. Additionally, ATM Inhibitor-3 exhibits favorable metabolic stability, making it a valuable tool for in vitro and in vivo studies. -
ATR Inhibitor
ATR-IN-6 is a selective inhibitor of ATR (ATM and Rad3-related), a serine/threonine kinase crucial for maintaining genomic stability and facilitating DNA damage repair, belonging to the phosphoinositide 3-kinase-related kinase (PIKK) family. This compound exhibits significant biological activity in the context of ATR-mediated pathways and holds promise for research in proliferative disorders and various cancer types. Its targeted inhibition of ATR can aid in the investigation of therapeutic strategies for diseases associated with DNA damage response dysfunction. -
ATR Inhibitor
ATR-IN-23 is a highly selective inhibitor of ATR (Ataxia Telangiectasia and Rad3-related protein) with an IC50 of 1.5 nM. This compound demonstrates significant antiproliferative activity against LoVo cancer cells and induces synthetic lethality in HT-29 cells. ATR-IN-23 is a valuable tool for investigating the mechanisms of DNA damage response (DDR) in cancer research, particularly in the context of DDR-deficient cancer types. -
ATM Inhibitor
ATM Inhibitor-4 is a potent and selective inhibitor of ATM (ataxia-telangiectasia mutated) kinase, exhibiting an IC50 of 0.32 nM. This compound demonstrates enhanced inhibition of the PI3K kinase family and achieves complete inhibition of mTOR at a concentration of 1 μM. Additionally, ATM Inhibitor-4 displays favorable metabolic stability, making it a valuable tool for research applications involving DNA damage response and cell cycle regulation. -
ATR Ligand
ATR-IN-30 is a selective ATR (ataxia telangiectasia and Rad3-related protein) ligand that plays a crucial role in disrupting ATR signaling pathways. This compound can be utilized for the development of ATR PROTACs, including PROTAC ATR degrader-2, facilitating targeted protein degradation studies. ATR-IN-30 is valuable for researchers investigating DNA damage response mechanisms and potential therapeutic avenues in cancer treatment. -
ATM Inhibitor
ATM Inhibitor-6 acts as a selective inhibitor of ATM kinase, interfering with the DNA damage response mechanism. It is valuable for studying cellular processes associated with DNA repair and the proliferation of cancer cells. This reagent is suitable for various cancer research applications, providing insights into the role of ATM in tumorigenesis and therapeutic resistance. -
ATM Inhibitor
ATM Inhibitor-11 is a potent ATM kinase inhibitor with an IC50 value of 0.32 nM. It effectively inhibits the phosphorylation of KAP1, demonstrating an IC50 of 0.97 nM. This compound shows significant pharmacokinetic properties, achieving high exposure levels in the brain, heart, and plasma of ICR mice. Additionally, ATM Inhibitor-11 displays notable anti-tumor activity in the NCI-H441 xenograft mouse model, making it a valuable tool for cancer research and therapeutic development. -
ATR ligand
ATR Ligand 2 targets the ATR protein as a PROTAC ligand, facilitating the degradation of ATR through the ubiquitin-proteasome system. By conjugating ATR Ligand 2 with an E3 ligase ligand and linker, researchers can synthesize PROTAC ATR degrader-3, enabling the selective modulation of ATR levels in cells. This compound is instrumental for studies focusing on DNA damage response, cancer therapeutics, and the mechanism of action of DNA-targeting agents. -
ATM/ATR Inhibitor
ATR-IN-10 is a selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase, exhibiting an IC50 value of 2.978 μM. This compound plays a crucial role in mediating the DNA damage response and is instrumental in studies related to cancer therapeutics, especially in enhancing the efficacy of DNA-damaging agents. ATR-IN-10 is particularly applicable in exploring the interplay between DNA repair mechanisms and cancer cell sensitivity, making it a valuable tool for research in oncology and molecular biology. -
ATR Inhibitor
ATR-IN-32 is a potent inhibitor of the ATR protein kinase, exhibiting oral bioavailability. This compound demonstrates a strong capacity to inhibit the proliferation of MIA PaCa-2 cells and effectively reduces tumor growth in mouse models bearing LOVO and HT-29 xenografts. ATR-IN-32 is applicable in the investigation of ATR-mediated cancer pathways, including those associated with colorectal and pancreatic cancers. -
ATR Inhibitor
ATR-IN-19 is a selective inhibitor of ATR (ATM and Rad3 related) kinase, functioning by disrupting the DNA damage response pathway. This compound has demonstrated potent biological activity in cellular models, making it an invaluable tool for studying the effects of ATR inhibition on cell cycle progression and DNA repair mechanisms. ATR-IN-19 can be employed in cancer research, particularly in investigating therapies that target DNA repair pathways in tumor cells. -
ATM Inhibitor
ATM-IN-1 is a specific inhibitor of Ataxia Telangiectasia Mutated (ATM) protein, which plays a crucial role in cell cycle regulation and the cellular response to DNA damage. By inhibiting ATM, this compound is instrumental in studying the mechanisms of cancer progression and neurological disorders. ATM-IN-1 is valuable for research applications focused on understanding the ATM signaling pathway and its implications in disease models. -
ATR Inhibitor
ATR-IN-15 is a potent inhibitor of ATR kinase, exhibiting an IC50 of 8 nM. This compound demonstrates significant inhibitory effects on human colon tumor cells (LoVo) as well as DNA-PK and PI3K, with IC50 values of 47 nM, 663 nM, and 5131 nM, respectively. ATR-IN-15 is valuable for research into DNA damage response pathways and cancer therapeutics. -
ATR Inhibitor
ATR-IN-21 is a potent inhibitor of Ataxia Telangiectasia and Rad3 related protein (ATR), exhibiting an IC50 value of less than 1000 nM. This compound effectively modulates the DNA damage response, making it valuable for research in cancer biology and therapeutic development. ATR-IN-21 can be utilized in studies exploring tumor cell sensitivity to genotoxic agents and the mechanistic pathways of DNA repair. -
ATR Inhibitor
ATR-IN-17 is a potent inhibitor of the Ataxia Telangiectasia and Rad3 related (ATR) kinase. Demonstrating significant anticancer activity, ATR-IN-17 exhibits an IC50 value of 1 nM in LoVo cells, making it a valuable tool for cancer research. This compound is primarily utilized in studies focusing on DNA damage response and cell cycle regulation. -
ATR Inhibitor
ATR-IN-22 is a potent inhibitor of Ataxia Telangiectasia and Rad3-related protein (ATR). This compound effectively reduces the proliferation of MIAPaCa-2 pancreatic cancer cells, exhibiting an IC50 of less than 1 μM. Additionally, ATR-IN-22 demonstrates significant anti-tumor activity in colon cancer, making it a valuable reagent for research into cancer biology and therapeutic development. -
ATM Inhibitor
ATM Inhibitor-2 is a highly potent and selective inhibitor of ataxia telangiectasia mutated (ATM) kinase, exhibiting an IC50 of less than 1 nM. This compound is valuable in studying DNA damage response mechanisms and cell cycle regulation. Researchers can utilize this inhibitor to explore potential therapeutic strategies in cancer treatments and related biological pathways. -
ATR Inhibitor
ATR-IN-20 is a potent inhibitor of ATR (Ataxia Telangiectasia and Rad3-related protein) with an IC50 value of 3 nM. In addition to its primary action on ATR, ATR-IN-20 also inhibits mTOR with an IC50 of 18 nM while demonstrating selectivity against PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). This compound shows a favorable pharmacokinetic profile with 30% oral bioavailability, indicating its potential for applications in anticancer research and therapeutic development. -
ATR Inhibitor
ATR-IN-8 is a potent inhibitor of ATR (ataxia telangiectasia and Rad3-related protein), a critical enzyme involved in the homologous recombination repair pathway and a member of the PIKK family. This compound demonstrates significant biological activity in disrupting ATR-mediated DNA damage response mechanisms, making it a valuable tool for cancer research. ATR-IN-8 can be utilized to investigate the therapeutic implications of ATR inhibition in various cancer models and studies related to DNA repair mechanisms. -
ATM Inhibitor
Antitumor agent-28 is a selective inhibitor of ataxia telangiectasia mutated (ATM) kinase. By inhibiting ATM activity, it disrupts DNA damage response pathways, demonstrating potent anti-cancer efficacy. This compound is valuable for research applications focused on cancer biology, DNA repair mechanisms, and therapeutic development. -
ATM Inhibitor
ATM-IN-12 is a specific inhibitor of ATM kinase, exhibiting an IC50 of 1.26 μM. This compound is instrumental in studying ATM kinase-mediated diseases, particularly in cancer research. By targeting ATM kinase, ATM-IN-12 provides valuable insights into the cellular responses to DNA damage and the mechanisms underlying tumorigenesis. -
ATR Kinase Inhibitor
ATR-IN-29 is a highly potent ATR kinase inhibitor, demonstrating an IC50 value of 1 nM. This compound exhibits significant antiproliferative activity, making it a valuable tool for investigating the role of ATR in cancer cell proliferation. ATR-IN-29 is ideal for studies focused on DNA damage response and cell cycle regulation, providing insights into therapeutic interventions for cancer treatment. -
ATR Inhibitor
ATR-IN-13 is a potent inhibitor of ATR kinase, exhibiting an IC50 of 2 nM. This compound is primarily utilized in research related to ATR kinase-mediated diseases, including proliferative disorders and various forms of cancer. Its specific inhibitory activity makes it a valuable tool for exploring the roles of ATR kinase in tumor biology and therapeutic interventions. -
ATM Kinase Inhibitor
ATM-IN-13 is a selective inhibitor of ATM kinase, exhibiting an IC50 of 0.3 nM in human cells. This compound effectively disrupts the ATM-mediated signaling pathway responsible for DNA double-strand break repair, resulting in decreased phosphorylation of ATM and p53 and inhibiting the ATM-dependent DNA damage response. ATM-IN-13 is a valuable tool for advancing research in colorectal cancer and understanding the mechanisms of DNA repair and cellular response to genotoxic stress. -
ATR Inhibitor
ATR-IN-18 is a potent and orally active ATR kinase inhibitor with an IC50 of 0.69 nM. It exhibits significant antiproliferative effects in LoVo cells, achieving an IC50 of 37.34 nM. Due to its inhibitory effects on ATR, ATR-IN-18 is relevant for research applications in cancer biology and therapeutic development. -
ATR Protein kinase Inhibitor
ATR kinase-IN-2 is a selective inhibitor of ATR protein kinase, exhibiting a Ki value ranging from 0.01 to 1 μM. This compound is valuable for investigating the role of ATR in DNA damage response pathways and its implications in cancer biology. Research applications include exploring tumor cell sensitivity to DNA-damaging agents and elucidating mechanisms of resistance to cancer therapies. -
ATR Inhibitor
ATR-IN-5 is a potent inhibitor of ATR (Ataxia Telangiectasia and Rad3-related protein), a member of the PI3K-related kinase family that plays a crucial role in maintaining genome stability and facilitating DNA damage repair. This compound is valuable for research into ATR kinase-mediated diseases, including various proliferative disorders and cancers. Its inhibitory effects on ATR provide a useful tool for investigating therapeutic strategies targeting DNA repair mechanisms in these conditions. -
ATM/ATR Inhibitor
ATM Inhibitor-9 is a selective inhibitor targeting ATM kinase, with an IC50 value of 5 nM. It effectively impairs ATM-mediated signaling pathways, making it an invaluable tool for cancer research, particularly in studies involving DNA damage response and repair mechanisms. This compound can be used to explore the role of ATM in tumor biology and therapeutic resistance. -
ATM Inhibitor
ATM Inhibitor-8 is a selective and potent inhibitor of Ataxia Telangiectasia Mutated (ATM) kinase, exhibiting an IC50 of 1.15 nM. This compound demonstrates significant anti-tumor activity, making it valuable for research in cancer biology and therapeutic development. Its oral bioavailability enhances its utility in in vivo studies exploring the role of ATM inhibition in various malignancies. -
ATR Protein Kinase Inhibitor
ATR kinase-IN-3 is a potent ATR protein kinase inhibitor with a Ki value ranging from 0.01 to 1 μM. This compound significantly modulates the ATR signaling pathway, making it valuable for studies in cancer biology, particularly in understanding DNA damage response mechanisms. Its ability to inhibit ATR activity can aid in assessing the therapeutic potential of targeting this pathway in various cancer models. -
ATR Inhibitor
ATR-IN-16 is a potent inhibitor of the ATR kinase, a critical regulator of the DNA damage response pathway. This compound demonstrates significant anticancer activity, exhibiting an IC50 of 410 nM in LoVo cells. ATR-IN-16 is applicable in cancer research, particularly for studies focused on DNA repair mechanisms and therapeutic strategies targeting ATR signaling. -
ATR Inhibitor
ATR-IN-33 is a selective ATR kinase inhibitor that targets the ataxia telangiectasia and Rad3-related protein, involved in the DNA damage response. By inhibiting ATR activity, ATR-IN-33 effectively impairs cellular repair mechanisms, which can lead to enhanced sensitivity to DNA-damaging agents. This compound is valuable for research applications in cancer biology, particularly in studies assessing tumor response to therapy and exploring mechanisms of resistance. -
ATR Inhibitor
Ceralasertib formate is a highly potent and selective inhibitor of ATR (ataxia telangiectasia and Rad3-related protein) with an IC50 value of 1 nM. This compound effectively inhibits cell viability, induces DNA damage, and promotes cellular senescence. Ceralasertib formate demonstrates notable antitumor activity and is valuable for research applications focused on cancer therapeutics and DNA damage response pathways. -
Mitochondrial RNA Probe
Biotin-aniline is a highly reactive probe targeting RNA and DNA, functioning effectively as a novel APEX2 substrate. Its unique properties allow for the labeling of proteins through miniSOG, making it an advantageous tool for capturing subcellular transcriptomes in living cells. Biotin-aniline offers superior spatial specificity, facilitating advanced studies in cellular dynamics and gene expression analysis. -
DNA-PK Inhibitor
NU-7031 is a coumarin derivative that selectively inhibits DNA-PK with an IC50 of 1.7 μM. This compound is utilized in cancer research to investigate DNA repair mechanisms and therapeutic strategies targeting DNA damage response pathways. Its role as a DNA-PK inhibitor makes it a valuable tool for understanding the implications of DNA repair in tumor biology. -
DNA-PK/mTOR Inhibitor
CC-115 hydrochloride is a potent dual inhibitor of DNA-PK and mTOR, exhibiting IC50 values of 13 nM and 21 nM, respectively. It effectively disrupts signaling pathways associated with both mTORC1 and mTORC2. This compound is valuable for research focused on cancer therapeutics and the modulation of DNA damage response mechanisms. -
DNA-PK Inhibitor
VX-984 is a potent and selective DNA-PK inhibitor that effectively penetrates the blood-brain barrier. It disrupts the non-homologous end joining (NHEJ) repair pathway, leading to an increase in DNA double-strand breaks (DSBs). This compound has significant research applications in the study of glioblastomas (GBM) and non-small cell lung cancer (NSCLC). Ideal for investigations into cancer therapy and DNA damage response mechanisms. -
DNA-PK Inhibitor
BAY-8400 is a potent and selective inhibitor of DNA-dependent protein kinase (DNA-PK), with an IC50 of 81 nM. This orally active compound is primarily employed in cancer research, where it can help elucidate DNA repair mechanisms and investigate therapeutic strategies targeting DNA damage response pathways. -
DNA-PK Inhibitor
DNA-PK-IN-12 is a potent DNA-PK inhibitor, displaying an IC50 of 0.1 nM. This compound effectively inhibits cell growth and Hct116 cell colony formation with an IC50 of 33.28 μM. Additionally, DNA-PK-IN-12 demonstrates significant antitumor activity in vivo, making it a valuable reagent for cancer research and therapeutic studies. -
DNA-PK Inhibitor
AMA-37 is an ATP-competitive inhibitor of DNA-dependent protein kinase (DNA-PK), demonstrating an IC50 value of 0.27 μM for this target. In addition, it shows moderate inhibitory activity against phosphoinositide 3-kinase isoforms with IC50 values of 32 μM for p110α, 3.7 μM for p110β, and 22 μM for p110γ. This compound is suitable for research applications focusing on DNA repair mechanisms and cancer therapeutics, where modulation of DNA-PK activity may be beneficial. -
DNA-PK Inhibitor
ZL-2201 is a potent inhibitor of DNA-dependent protein kinase (DNA-PK) with an IC50 value of 1 nM. This compound plays a critical role in the study of DNA repair mechanisms and cellular responses to DNA damage. It is valuable for researchers investigating cancer biology, therapeutic resistance, and the modulation of DNA repair pathways. -
DNA-PK Inhibitor
DNA-PK-IN-8 is a selective and potent inhibitor of DNA-dependent protein kinase (DNA-PK) with an IC50 value of 0.8 nM. This compound displays synergistic antiproliferative effects on various cancer cell lines and significantly reduces HL-60 tumor growth when used in combination with Doxorubicin. DNA-PK-IN-8 is an invaluable tool for studying DNA repair mechanisms and exploring therapeutic strategies in oncology research. -
DNA-PK Inhibitor
NU5455 is a selective and potent inhibitor of DNA-dependent protein kinase catalytic subunit (DNA-PKcs). This compound significantly enhances the efficacy and toxicity of parenterally administered topoisomerase inhibitors, particularly Doxorubicin, in liver tumor xenografts, while maintaining a favorable safety profile. NU5455 is valuable in cancer research, specifically in studies focused on DNA repair mechanisms and therapeutic strategies for optimizing chemotherapeutic outcomes. -
DNA-PK Inhibitor
DNA-PK-IN-15 is a potent inhibitor of DNA-dependent protein kinase (DNA-PK) with an IC50 of 0.08 nM. This compound effectively hinders DNA repair mechanisms, making it a valuable tool for studying the cellular responses to DNA damage and the effects of DNA-PK modulation in various biological contexts. Research applications include cancer therapy development and understanding the role of DNA-PK in genomic stability. -
DNA-PK Inhibitor
DNA-PK-IN-2 is a potent inhibitor of DNA-dependent protein kinase (DNA-PK), a critical enzyme complex involved in DNA repair, consisting of Ku70/Ku80 heterodimer and DNA-PK catalytic subunit (DNA-PKcs). This compound is designed for research applications focused on cancer biology, where modulation of DNA repair pathways is essential. DNA-PK-IN-2 may provide insights into cancer treatment strategies by disrupting DNA repair mechanisms in tumor cells.
